MX2009005222A - Derivados de pirrolina contra la liberacion del factor de necrosis tumoral en celulas; metodos de preparacion y su uso. - Google Patents

Derivados de pirrolina contra la liberacion del factor de necrosis tumoral en celulas; metodos de preparacion y su uso.

Info

Publication number
MX2009005222A
MX2009005222A MX2009005222A MX2009005222A MX2009005222A MX 2009005222 A MX2009005222 A MX 2009005222A MX 2009005222 A MX2009005222 A MX 2009005222A MX 2009005222 A MX2009005222 A MX 2009005222A MX 2009005222 A MX2009005222 A MX 2009005222A
Authority
MX
Mexico
Prior art keywords
preparation methods
alkyl
against cell
necrosis factor
tumor necrosis
Prior art date
Application number
MX2009005222A
Other languages
English (en)
Inventor
Hesheng Zhang
Original Assignee
Tianjin Hemay Bio Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Hemay Bio Tech Co Ltd filed Critical Tianjin Hemay Bio Tech Co Ltd
Publication of MX2009005222A publication Critical patent/MX2009005222A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Compuestos representados por la fórmula (I) o (II), contra la liberación de FNTa en las células; sus sales o hidratos aceptables para uso farmacéutico y los métodos de preparación y sus usos; en los que A y B representan CH2, CO, SO, SO2, respectivamente; D representa S, NH, N-alquilo de 1 a 6 átomos de carbono; R1 representa H, uno o dos radiales iguales o diferentes, seleccionados del grupo que consiste de F, Cl, Br, alquilo de 1 a 4 átomos de carbono, OH, O-alquilo de 1 a 4 átomos de carbono, NO2, NHC(O)-alquilo de 1 a 4 átomos de carbono, NH2, NH(alquilo de 1 a 4 átomos de carbono), N(alquilo de 1 a 4 átomos de carbono)2. (ver fórmula (I) y (II)).
MX2009005222A 2006-11-15 2007-10-16 Derivados de pirrolina contra la liberacion del factor de necrosis tumoral en celulas; metodos de preparacion y su uso. MX2009005222A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200610129421A CN101186612B (zh) 2006-11-15 2006-11-15 可抑制细胞释放肿瘤坏死因子的吡咯啉衍生物及其制备和应用
PCT/CN2007/002965 WO2008058448A1 (fr) 2006-11-15 2007-10-16 Dérivés de pyrroline agissant contre les cellules libérant le facteur de nécrose tumorale, procédés de préparation et utilisations associés

Publications (1)

Publication Number Publication Date
MX2009005222A true MX2009005222A (es) 2009-07-02

Family

ID=39401313

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005222A MX2009005222A (es) 2006-11-15 2007-10-16 Derivados de pirrolina contra la liberacion del factor de necrosis tumoral en celulas; metodos de preparacion y su uso.

Country Status (12)

Country Link
US (1) US8466191B2 (es)
EP (1) EP2083011B1 (es)
JP (1) JP5491863B2 (es)
KR (1) KR20090086592A (es)
CN (1) CN101186612B (es)
AU (1) AU2007321636A1 (es)
BR (1) BRPI0716005A2 (es)
CA (1) CA2669357A1 (es)
ES (1) ES2498797T3 (es)
MX (1) MX2009005222A (es)
RU (1) RU2473551C2 (es)
WO (1) WO2008058448A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107964016B (zh) * 2009-05-14 2021-10-01 天津合美医药科技有限公司 噻吩衍生物
WO2011143444A2 (en) * 2010-05-14 2011-11-17 President And Fellows Of Harvard College Diphenylbutypiperidine autophagy inducers
MX2019007434A (es) * 2016-12-21 2019-08-16 Biotheryx Inc Derivados de tienopirrol para uso en seleccion como diana de proteinas, composiciones, metodos y usos de los mismos.
US10570147B2 (en) * 2017-06-13 2020-02-25 Biotheryx, Inc. Bicyclic compounds and methods of use
KR20210025001A (ko) 2018-05-02 2021-03-08 톈진 헤메이 파마슈티칼 컴퍼니 리미티드 티오펜 유도체의 결정형
CN116332954A (zh) * 2021-12-21 2023-06-27 赣州和美药业股份有限公司 噻吩衍生物的制备

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2571723B1 (fr) * 1984-10-12 1988-08-26 Lipha Derives de thieno et furo-(2,3-c) pyrroles, procedes de preparation et medicaments les contenant
FI862513A (fi) * 1985-07-04 1987-01-05 Chemie Linz Ag Nya tieno-1,2-tiazolderivat, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska preparat.
US4732984A (en) * 1985-10-17 1988-03-22 American Home Products Corporation Piperazinoisothiazolones with psychotropic activity
ATA39088A (de) * 1988-02-18 1990-06-15 Binder Dieter Dr Basisch substituierte thienoisothiazol-3(2h)-on-1,1-dioxide und ihre pharmazeutisch vertraeglichen salze, verfahren zu ihrer herstellung und ihre verwendung
DE4023048A1 (de) * 1990-07-20 1992-01-23 Basf Ag Dicarbonsaeureimide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
EP0599697A1 (fr) * 1992-11-24 1994-06-01 Synthelabo Dérivés de pyrrole, leur préparation et leur application en thérapeutique
US5334596A (en) * 1993-05-11 1994-08-02 Merck & Co., Inc. Fibrinogen receptor antagonists
US5728844A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
SE9702001D0 (sv) * 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
DE19858193A1 (de) * 1998-12-17 2000-06-21 Aventis Cropscience Gmbh 4-Trifluormethyl-3-oxadiazolylpyridine, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel
WO1999046267A1 (en) * 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
CN100384836C (zh) * 2000-02-29 2008-04-30 三菱制药株式会社 新型环状酰胺衍生物
US7253167B2 (en) * 2004-06-30 2007-08-07 Bristol-Myers Squibb Company Tricyclic-heteroaryl compounds useful as kinase inhibitors
US8703795B2 (en) * 2005-03-02 2014-04-22 Fibrogen, Inc. Thienopyridine compounds, and methods of use thereof
CN100383139C (zh) * 2005-04-07 2008-04-23 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物
CN1939922B (zh) * 2005-09-27 2010-10-13 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3，4-c]吡咯-4，6-二酮衍生物
AR059036A1 (es) * 2006-01-17 2008-03-12 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios

Also Published As

Publication number Publication date
KR20090086592A (ko) 2009-08-13
CN101186612A (zh) 2008-05-28
JP2010509377A (ja) 2010-03-25
CN101186612B (zh) 2012-10-03
RU2009121676A (ru) 2010-12-20
EP2083011A1 (en) 2009-07-29
US20100179189A1 (en) 2010-07-15
EP2083011B1 (en) 2014-06-04
BRPI0716005A2 (pt) 2014-05-13
AU2007321636A1 (en) 2008-05-22
CA2669357A1 (en) 2008-05-22
RU2473551C2 (ru) 2013-01-27
EP2083011A4 (en) 2011-03-09
US8466191B2 (en) 2013-06-18
ES2498797T3 (es) 2014-09-25
JP5491863B2 (ja) 2014-05-14
WO2008058448A1 (fr) 2008-05-22

Similar Documents

Publication Publication Date Title
MX2009005222A (es) Derivados de pirrolina contra la liberacion del factor de necrosis tumoral en celulas; metodos de preparacion y su uso.
UA94052C2 (uk) Похідні піридазину
LUC00155I1 (es)
MY138941A (en) Aryl-pyridine derivatives
TW200744659A (en) Preparation for preventing and ameliorating wrinkle
MX2009013078A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotropicos de glutamato - 842.
GB0714228D0 (en) Oral compositions. Their preparation and use
MY139475A (en) Process for the preparation of (1s)-4,5-dimethoxy-1-(methylaminomethyl)-benzocyclobutane, acid addition salts thereof and its use for the synthesis of ivabradine and for its pharmaceutically acceptable acid addition salts
GEP20104895B (en) Preparation of pregabalin and related compounds
WO2007048065A3 (en) Pyrimidinones as casein kinase ii (ck2) modulators
TW200616976A (en) Pyrimidine derivatives
EA201001015A1 (ru) Карбамоиловые соединения в качестве ингибиторов dgat1 190
TW200744588A (en) Pharmaceutical composition for external use
TW200716151A (en) Polymeric derivative of cytidine metabolic antagonist
SG170049A1 (en) Novel 11 beta - hydroxyandrosta-4-ene-3-ones
TW200734309A (en) Water-soluble benzoazepine compound and its pharmaceutical composition
ECSP077402A (es) Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica
MX2009003169A (es) Derivados de sulfonamida.
WO2009153461A3 (fr) Nouveau procede de synthese de la 7,8-dimethoxy-1,3-dihydro-2h-3- benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
IL200469A0 (en) Benzimidazole derivatives
MX2008001560A (es) Nuevos compuestos analogos de la camptotecina, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
UA87146C2 (ru) Производные диарилметилпиперазина, способ их получения и фармацевтическая композиция на их основе
WO2007007207A8 (en) Pharmaceutical compositions of 3, 5 -bis (arylidene) -4 -piperidones and analogues there of for modulating cell proliferation
EP2093228A4 (en) PYRROLINE-2-ONE DERIVATIVES FOR CELL-RELEASED TUMOR NECROSIS FACTOR, PREPARATION METHODS AND USES THEREOF
RS20060239A (en) Arylalkylcarbamate derivatives, preparation method thereof and use of same in therapeutics

Legal Events

Date Code Title Description
FA Abandonment or withdrawal